You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2024

Roche Palo Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ROCHE PALO, and what generic and branded alternatives to ROCHE PALO drugs are available?

ROCHE PALO has thirteen approved drugs.

Summary for Roche Palo

US Patents:	0
Tradenames:	7
Ingredients:	8
NDAs:	13
Patent Litigation for Roche Palo:	See patent lawsuits for Roche Palo

Drugs and US Patents for Roche Palo

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche Palo	EVEX	estrogens, esterified	TABLET;ORAL	084215-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Roche Palo	CELLCEPT	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	050758-001	Aug 12, 1998	AP	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Roche Palo	CELLCEPT	mycophenolate mofetil	CAPSULE;ORAL	050722-001	May 3, 1995	AB	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
Roche Palo	EVEX	estrogens, esterified	TABLET;ORAL	083376-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Roche Palo	TORADOL	ketorolac tromethamine	INJECTABLE;INJECTION	019698-001	Nov 30, 1989		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-001	Mar 24, 1993		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Roche Palo

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997	4,423,050	⤷ Subscribe
Roche Palo	CELLCEPT	mycophenolate mofetil	FOR SUSPENSION;ORAL	050759-001	Oct 1, 1998	4,753,935	⤷ Subscribe
Roche Palo	CELLCEPT	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	050758-001	Aug 12, 1998	5,543,408	⤷ Subscribe
Roche Palo	TORADOL	ketorolac tromethamine	TABLET;ORAL	019645-001	Dec 20, 1991	4,089,969	⤷ Subscribe
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997	4,642,346	⤷ Subscribe
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-002	Oct 31, 1991	4,051,141	⤷ Subscribe
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-001	Mar 24, 1993	4,051,141	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ROCHE PALO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Oral Suspension	200 mg/mL	➤ Subscribe	2011-03-25

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.